When we think of the letters N-F-L, our minds are drawn to football and the National Football League. However, NfL, or ineurofilament light chain as the non-abbreviated name, is also a powerful protein that has shown promise for the early detection and diagnosis of brain injuries, as well as several neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease.
We are privileged to live in a society that values science, technology, engineering and mathematics. Better known as STEM, these programs play a critical role in the advancement of our society, and are shaping the future of medicine and other disciplines. STEM makes it possible for our children to live in a world where diseases can be detected before symptoms are present and developing nations can implement sustainable initiatives to end poverty.
We were honored to be able to speak about the promise of immuno-oncology (IO) therapeutics at this year’s Molecular Med Tri-Con conference and the 12th Annual Biomarkers Congress. Bringing together thought leaders from around the world, including academics, pharma customers and therapeutic companies, these conferences are critical for the acceleration of precision health for improved treatment methods across a variety of disease-types.
2016 has been a banner year for the healthcare and life sciences industries. This year we saw the launch of critical initiatives like the Vice President Biden’s Cancer Moonshot, aimed at improving our ability to prevent cancer and detect it an early stage. As recently as just this month, we saw the passing of the 21st Century Cures Act, an important step forward in transformation of our approach to precision health, in part by providing funding to some of our most promising research initiatives, setting us up to continue to achieve incredible milestones in 2017 and beyond.